Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders

Competing Interest Statement

Disclosure: Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals and Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.

Funding Statement

Funding: T32DA007261 (ASH), DA54869 (AA, JG, HE), DA54750 (AA, RB), K02DA32573 (AA), R21AA027827 (RB), K01DA51759 (ECJ), DP1DA54394 (SS-R), R01AA027522 (AE), F31AA029934 (SEP), R01MH120219 (EMTD, ADG), RF1AG073593 (EMTD, ADG), P30AG066614 (EMTD), P2CHD042849 (EMTD), R33DA047527 (RP, GAP), T32 AA028259 (JDD)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data Availability: The MVP publicly available summary statistics were obtained via an approved dbGaP application (phs001672.v4.p1). The authors thank Million Veteran Program (MVP) staff, researchers, and volunteers, who have contributed to MVP, and especially participants who previously served their country in the military and now generously agreed to enroll in the study. Information for Opioid use disorder and problematic alcohol use was taken from this dbGAP application (For details, see https://www.research.va.gov/mvp/ and Gaziano, J.M. et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70, 214-23 (2016)). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) Cooperative Studies Program (CSP) award #G002. Publicly available summary statistics for alcohol dependence and cannabis use disorder were also taken from the psychiatric genomics consortium: https://www.med.unc.edu/pgc/. Publicly available summary statistics for smoking were taken from the authors of PMCID: PMC5882602 upon request and from the GSCAN consortium: https://conservancy.umn.edu/handle/11299/201564

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes